If an expensive, name-brand cholesterol drug costs four times more than a generic but provides no clear clinical benefit, why do insurers—both public and private—continue to pay for it? The answer, in the case of Vytorin, a combination of two...
Read More...
Read the complete post at http://www.healthbeatblog.com/2009/11/mercks-cholesterol-drugslow-hanging-fruit.html
Posted
Nov 25 2009, 02:21 PM
by
Health Beat